Avantor, Inc. (NYSE:AVTR) Stock Has Average Target Price of $12.47

Avantor, Inc. (NYSE:AVTR) has received an average recommendation of “Hold” from the eighteen research firms that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and two have assigned a buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $12.88.

A number of equities analysts have recently commented on AVTR shares. Citigroup lifted their target price on shares of Avantor from $9.00 to $11.00 and gave the company a “neutral” rating in a report on Wednesday, July 8th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $13.00 price target on shares of Avantor in a research note on Thursday, July 30th. Stifel Nicolaus increased their price target on shares of Avantor from $8.00 to $15.00 and gave the stock a “hold” rating in a research note on Thursday, July 30th. Morgan Stanley raised their price objective on shares of Avantor from $10.00 to $14.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 30th. Finally, TD Cowen restated a “hold” rating on shares of Avantor in a research note on Wednesday, July 15th.

Institutional Investors Weigh In On Avantor

Several hedge funds have recently made changes to their positions in AVTR. Elevation Wealth Partners LLC raised its position in Avantor by 72.3% during the 3rd quarter. Elevation Wealth Partners LLC now owns 2,803 shares of the company’s stock worth $42,000 after buying an additional 1,176 shares during the last quarter. SJS Investment Consulting Inc. lifted its stake in shares of Avantor by 1,599.7% in the 1st quarter. SJS Investment Consulting Inc. now owns 5,235 shares of the company’s stock worth $41,000 after acquiring an additional 4,927 shares during the period. IFP Advisors Inc lifted its stake in shares of Avantor by 901.4% in the 2nd quarter. IFP Advisors Inc now owns 5,858 shares of the company’s stock worth $58,000 after acquiring an additional 5,273 shares during the period. State of Wyoming purchased a new stake in shares of Avantor in the second quarter valued at about $74,000. Finally, Parallel Advisors LLC boosted its holdings in shares of Avantor by 21.4% in the first quarter. Parallel Advisors LLC now owns 8,452 shares of the company’s stock valued at $66,000 after acquiring an additional 1,491 shares in the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

Avantor Stock Up 0.1%

Shares of NYSE AVTR opened at $15.69 on Wednesday. The stock has a market cap of $10.61 billion, a PE ratio of -18.68, a price-to-earnings-growth ratio of 11.83 and a beta of 0.94. The company has a quick ratio of 1.18, a current ratio of 1.78 and a debt-to-equity ratio of 0.65. Avantor has a 52-week low of $7.26 and a 52-week high of $16.38. The business has a 50-day moving average price of $14.67 and a 200 day moving average price of $11.14.

Avantor (NYSE:AVTR) last released its quarterly earnings results on Wednesday, July 29th. The company reported $0.21 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.19 by $0.02. The firm had revenue of $1.69 billion for the quarter, compared to the consensus estimate of $1.61 billion. Avantor had a positive return on equity of 9.92% and a negative net margin of 8.81%. The firm’s quarterly revenue was up .5% compared to the same quarter last year. During the same quarter last year, the business posted $0.24 EPS. Avantor has set its FY 2026 guidance at 0.800-0.830 EPS. Equities research analysts forecast that Avantor will post 0.81 earnings per share for the current year.

Avantor Company Profile

Avantor, Inc is a global provider of products, services and solutions used in the life sciences and advanced technology industries. The company supplies materials and equipment that support research, drug discovery and development, biopharmaceutical manufacturing, clinical and diagnostic activities, and other laboratory applications.

Its offerings include laboratory chemicals and reagents, consumables, single-use manufacturing technologies, bioprocessing products, equipment, and related services.